IP platform sale for $20 million; Product available at Walmart, Bed Bath & Beyond & Target: Stock symbol: CURR

CURR and Sera Labs

CURR and Nicole Kidman

CURR products

CURR Sera Topical

Movie CURR

IP platform sale for $20 million; Health & Beauty Lines Available at Walmart, Bed Bath & Beyond, CVS & Target.com : (Stock symbol: CURR)

CURE PHARMACEUTICAL HOLDING CORP (OTCMKTS:CURR)

CURR is hosting a conference call on Wednesday, August 3, 2022 at 5:00 PM EST to discuss the recent $20 million non-dilutive sale of a small portion of its portfolio of products and intellectual property”

— CURR Company

OXNARD, CALIFORNIA, UNITED STATES, Aug. 1, 2022 /EINPresswire.com/ — IP Platform Sale for $20 Million; Health & Beauty Lines Available at Walmart, Bed Bath & Beyond, CVS & Target.com: CURE Pharmaceutical (Stock symbol: CURR)

Proceeds will be used to grow CURR’s wellness and beauty brands and the platform’s remaining proprietary technology

 Patented techniques improve efficacy, safety and patient experience.

 25,000 square feet, FDA, NSF registered® and a cGMP-certified manufacturing facility.

 Oral vitamin D supplementation is more effective than standard supplementation in achieving sufficient vitamin D before and after surgery.

 The skin care line is sold at select Walmart, CVS and Bed Bath & Beyond Stores.

 Oral Thin Film Strip, Nutri-Strips™ on shelves at CVS and at Target.com.

 Collaboration with Milagro Pharmaceuticals for registration and marketing approval of oral thin film sildenafil for the treatment of ED in Mexico.

 Patent approval for CUREfilm Blue™ technology for the treatment of ED.

CURR sold some of its platform technology intellectual property and related assets for a total of $20 million. CURR is using a portion of the cash proceeds to repay certain debt obligations and the balance will be used to grow its intellectual property portfolio and its wellness and beauty brands. In addition, CURR has retained its remaining proprietary technology on the platform, which it intends to monetize by commercializing the technology or by licensing or selling the technology.

CURR will host a conference call on August 3, 2022 to provide a full corporate update to shareholders. Details of the conference call will be provided on August 1, 2022 in a subsequent press release.

About CURR:

CURE Pharmaceutical (OTCQB: CURR) is a fully integrated and progressive drug delivery company. The CURR team has extensive experience in formulating and manufacturing over-the-counter, pharmaceutical and veterinary drugs, putting quality and service as their top priorities, earning the trust and respect of customers around the world.

CURR pioneered the development of CUREform™, a proprietary drug delivery platform that offers a number of unique immediate and controlled release drug delivery technologies designed to improve efficacy, safety and patient experience for a wide range of active ingredients. CURR delivery technologies include CUREfilm®, advanced oral thin film; and CUREdrops™, an emulsion technology that can be incorporated into various dosage forms (film, tincture, beverages, etc.), among others. CURR’s proprietary clinical pipeline includes CUREfilm®Blue (sildenafil for the treatment of erectile dysfunction) and CUREfilm®Canna (THC and CBD).

As a vertically integrated company, CURR operates a 25,000 sq. ft. FDA, NSF registered® and a cGMP-certified manufacturing facility that allows it to partner with pharmaceutical and wellness companies worldwide for proprietary and white-label manufacturing. CURR currently has partnerships in the US, China, Mexico, Canada, Israel and other markets in Europe.

 Positive results from a study at Cincinnati Children’s Hospital Medical Center using CURR’s patented oral thin-film high-dose, single-dose vitamin D in pediatric patients before and after hematopoietic stem cell transplantation

On May 12, CURR announced positive results from a study conducted at Cincinnati Children’s Hospital Medical Center using CURR’s proprietary, single-dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURR oral vitamin D supplementation was found to be more effective than standard supplementation in achieving vitamin D sufficiency before and after surgery, which is critical for reducing immune-mediated organ damage in children receiving HSCT.

To view the details of this study, visit the poster presentation on the CURR website at https://curepharmaceutical.com/white-papers/

 The products of CURR subsidiary Sera Labs Inc. now available at Walmart, Bed Bath & Beyond, CVS and Target.com

On April 14, CURR wholly-owned subsidiary Sera Labs announced that its Seratopical Revolution skin care line will be sold at select Walmart stores, as well as CVS and Bed Bath & Beyond stores. CURR also earned shelf space for its revolutionary oral thin film strip, Nutri-Strips™ on CVS and Target.com shelves. Nutri-Strip technology is proprietary to Sera Labs and is the result of years of research and more than 25 patents by the CURR development team.

 CURR and Milagro Pharmaceuticals Collaborate for Registration and Marketing Approval of Sildenafil Oral Thin Film in Mexico

On March 3, CURR and Milagro Pharmaceuticals, seeking an advantage in target health and wellness markets through a key collaboration, announced their collaboration to register and sell in Mexico a number of CURR OTC and medicinal compounds that use CUREform™, CURR’s proprietary delivery of oral thin film (OTF) platform drugs.

OTF products that will be marketed and sold in Mexico through key distribution partners include:

CUREfilm Blue™ – an orally soluble form of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED).

Vitamin D3 – provides a convenient weekly dose of 40,000 IU of vitamin D

Electrolyte Energy Boost – which provides a healthier, sugar-free alternative to energy drinks

Sleep – a dose of melatonin that dissolves on the tongue so it can be taken even after getting into bed.

 Patent approval for CUREfilm Blue™ technology

On November 16, CURR announced that it had received a notice of issue from the United States Patent Office (USPTO)

CUREfilm Blue™ uses CURR’s patented and proprietary fast-dissolving drug delivery platform known as CUREfilm™ to deliver the active pharmaceutical ingredient (API) sildenafil citrate.

For more information about CURE Pharmaceutical, Inc. (OTCQB: CURR) visit: www.curepharmaceutical.com and www.Seralabshealth.com

DISCLAIMER 1: Products mentioned are THC free and/or 2018 Farm Bill compliant.

DISCLAIMER 2: This article is for informational purposes only and is not a recommendation in any way to buy or sell any stock

Mike Reddard
CURE PHARMACEUTICAL HOLDING CORP
6176823625 ext.
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn
others

Nicole Kidman’s skincare: @Susan Yara’s reaction & thoughts | #SKIN CARE

Leave a Comment